

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. Mercy Hospital Joplin</p>	<p>In accordance with letter dated August 22, 2016,</p>	<p>4. Expiration Date: December 31, 2023</p>
<p>2. 100 Mercy Way Joplin, MO 64804</p>	<p>3. License number: 24-01090-03 is amended in its entirety to read as follows:</p>	<p>5. Docket No.: 030-12728 Reference No.:</p>
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>C. 400 millicuries total</p> <p>9. Authorized use</p> <p>A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.</p> <p>B. Any imaging and localization study permitted by 10 CFR 35.200.</p> <p>C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.</p>



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
24-01090-03

Docket or Reference Number
030-12728

Amendment No. 60

- | | | | |
|---|--|--|---|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license | 9. Authorized use |
| D. Iodine-125 permitted by 10 CFR 35.400 | D. Sealed Sources (Bard Brachytherapy, Inc., Model STM 1251; Best Medical International, Model 2300 Series; Core Oncology, Inc., Model I-125SH; I-125SL; International Brachytherapy, Inc., Model 1251L; IsoAid, Model IAI-125A; Medi-Physics, Model 6711; 6733; North American Scientific, Inc., Model MED 3631; Syneor, Model BT-125J) | D. 800 millicuries total | D. Any manual brachytherapy procedure permitted by 10 CFR 35.400. |
| E. Palladium-103 permitted by 10 CFR 35.400 | E. Sealed Sources (Best Medical International, Model 2300 Series; International Brachytherapy, Inc., Model 1031L; North American Scientific, Inc., Model MED 3633; Theragenics Corp., Model 200) | E. 800 millicuries total | E. Any manual brachytherapy procedure permitted by 10 CFR 35.400. |
| F. Gold-198 permitted by 10 CFR 35.400 | F. Sealed Sources (Best Medical International, Model 81-02) | F. 500 millicuries total | F. Any manual brachytherapy procedure permitted by 10 CFR 35.400. |
| G. Cesium-131 permitted by 10 CFR 35.400 | G. Sealed Sources (IsoRay, Model CS-1 Lawrence CESERION Cs-131) | G. 5 curies total | G. Any manual brachytherapy procedure permitted by 10 CFR 35.400. |



CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at 100 Mercy Way, Joplin, Missouri.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

24-01090-03

Docket or Reference Number

030-12728

Amendment No. 60

11. The Radiation Safety Officer for this license is Samuel Rhoades, Ph.D.

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User(M.D.,D.O.,etc.)

Richard J. Price, M.D.

Steven J. Taggart, M.D.

Lance H. Borup, D.O.

Francis H. Corcoran, M.D.

Duane Eugene Myers, M.D.

Jose Maria Pacheco-Gil, M.D.

Jacob Andrew Sedrick, D.O.

Grzegorz Mariusz Szarnecki, M.D.

Thomas Kevin Ceballos, M.D.

Material and Use

10 CFR 35.100 and 35.200.

10 CFR 35.100, 35.200 and 35.300.

10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

10 CFR 35.100 and 35.200.


10 CFR 35.300 and 35.400.

10 CFR 35.300.

10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131).

10 CFR 35.100 and 35.200.

10 CFR 35.100 and 35.200.



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
24-01090-03Docket or Reference Number
030-12728

Amendment No. 60

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated October 1, 2013 (ML13281A935)
- B. Letter received April 22, 2014 (ML14022A205)
- C. Letter dated December 3, 2014 (ML14339A761)
- D. Letter dated March 23, 2015 (ML15090A609)
- E. Letter dated April 30, 2015 (ML15127A342)
- F. Letter dated February 12, 2016 (ML16047A351)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: April 4, 2017By: Colleen Carol CaseyColleen Carol Casey
Region 3